<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144635</url>
  </required_header>
  <id_info>
    <org_study_id>KULDS-001</org_study_id>
    <nct_id>NCT03144635</nct_id>
  </id_info>
  <brief_title>A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir</brief_title>
  <official_title>A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regimen using grazoprevir plus elbasvir treatment is promising in Japan, because it may
      safely be used for the elderly patients with renal dysfunction. Grazoprevir and elbasvir are
      metabolized in the liver and do not require dose-adjustment for patients with renal
      dysfunction. However, no data related to efficacy and safety of the grazoprevir plus elbasvir
      treatment for Japanese elderly patients with renal dysfunction (eGFR&lt;60 mL/min/1.73m2) have
      been reported. Therefore, physicians are at a loss whether or not to treat the patients with
      renal dysfunction due to no evidence.

      The aim of this study is to investigate the improvement of serum endostatin level of Japanese
      patients with CKD stage 3 after grazoprevir (NS3/4A protease inhibitor) plus elbasvir (NS5A
      replication complex inhibitor) treatment by a prospective, multicenter cohort study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function at 12 weeks after the treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Change of serum endostatin level (ng/mL) from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal function at 12 weeks after the treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Change of serum eGFR level (mL/min/1.73m^2) from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained virological response-12 (SVR12)</measure>
    <time_frame>3 months</time_frame>
    <description>Serum HCV RNA (logIU/mL) at 12 weeks after the completion of administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical effect</measure>
    <time_frame>6 months</time_frame>
    <description>Change of serum alanine aminotransferase (ALT) level (U/L) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical effect</measure>
    <time_frame>6 months</time_frame>
    <description>Change of serum alpha-fetoprotein level (ng/mL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical effect</measure>
    <time_frame>6 months</time_frame>
    <description>Change of total cholesterol level (mg/dL) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of discontinuation (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of ALT abnormality (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>6 months</time_frame>
    <description>Other important medical events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between SVR12 and drug resistance mutations in NS3/4A and NS5A regions of HCV genome</measure>
    <time_frame>3 months</time_frame>
    <description>Drug resistance of HCV genome</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatitis C Viral</condition>
  <condition>Chronic Kidney Disease stage3</condition>
  <arm_group>
    <arm_group_label>Grazoprevir plus Elbasvir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir 100 mg plus Elbasvir 50 mg per day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir plus Elbasvir</intervention_name>
    <description>An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.</description>
    <arm_group_label>Grazoprevir plus Elbasvir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged 20 years or older.

          2. Patients positive for HCV RNA for over 6 months and infected with genotype 1b chronic
             hepatitis C, including compensated cirrhosis.

          3. Patients without co-infection of hepatitis B virus.

          4. Patients without co-infection of human immunodeficiency virus

          5. Patients with moderate chronic kidney disease (CKD stage 3) (eGFR: 30-59
             mL/min/1.73m2). A diagnosis of CKD is only confirmed if repeated eGFR tests for at
             least 90 days.

        Exclusion Criteria:

          1. Patients with decompensated cirrhosis (Child Pugh B and C)

          2. Patients with albumin &lt;3.0 g/dL and platelets &lt;75,000 /μL

          3. Patients with autoimmune hepatitis

          4. Constant heavy alcohol drinkers (converted to ethanol ≥60 g/day)

          5. Patients who have a history of hypersensitivity to grazoprevir and elbasvir

          6. Patients who are pregnant females, or females who may become pregnant, or females who
             are breastfeeding

          7. Patients with heart disease that is hard to control (e.g., very recent cardiac
             infarction, severe heart failure, unstable arrhythmia)

          8. Patients who are under medication with drugs listed as contraindication in a package
             insert of grazoprevir plus elbasvir treatment

          9. Patients judged (by the physician in charge of research) to be inappropriate as
             subjects for the study for any other reasons.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norihiro Furusyo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyushu University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eiichi Ogawa, MD, PhD</last_name>
    <phone>+81-92-642-5909</phone>
    <email>eogawa@gim.med.kyushu-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eiichi Ogawa, MD, PhD</last_name>
      <phone>+81-92-642-5909</phone>
      <email>eogawa@gim.med.kyushu-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. J Hepatol. 2013 Aug;59(2):205-12. doi: 10.1016/j.jhep.2013.03.020. Epub 2013 Mar 28.</citation>
    <PMID>23542346</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogawa E, Furusyo N, Yamashita N, Kawano A, Takahashi K, Dohmen K, Nakamuta M, Satoh T, Nomura H, Azuma K, Koyanagi T, Kotoh K, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study(KULDS) Group. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis. Hepatol Res. 2017 Mar;47(3):E120-E131. doi: 10.1111/hepr.12738. Epub 2016 Jun 10.</citation>
    <PMID>27142311</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogawa E, Furusyo N, Kajiwara E, Nomura H, Kawano A, Takahashi K, Dohmen K, Satoh T, Azuma K, Nakamuta M, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. J Gastroenterol Hepatol. 2015 Dec;30(12):1759-67. doi: 10.1111/jgh.13016.</citation>
    <PMID>26095167</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Norihiro Furusyo</investigator_full_name>
    <investigator_title>Associate Professor, Department of General Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Direct Acting Antivirals</keyword>
  <keyword>Grazoprevir</keyword>
  <keyword>Elbasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

